Xueshuantong injection (lyophilized) combined with salvianolate lyophilized injection protects against focal cerebral ischemia/reperfusion injury in rats through attenuation of oxidative stress Abstract Salvianolate lyophilized injection (SLI) and Xueshuantong injection (lyophilized) (XST) are two herbal standardized preparations that have been widely used in China for the treatment of acute cerebral infarction. In this study, we investigated the neuroprotective effects of SLI combined with XST in a rat model of middle cerebral artery occlusion-reperfusion (MCAO/R). Wistar rats were subjected to 1.5 h of MCAO followed by reperfusion for 3 h, then were treated with SLI or XST alone, or with their combinations via tail vein injection daily for 3 d. Edaravone (EDI, 6 mg·kg -1 ·d -1 ) was used as a positive control drug, We showed that administration of a combination of 1X1S (XST 100 mg·kg -1 ·d -1 plus SLI 21 mg·kg -1 ·d -1 ) more effectively protected the ischemic brains than SLI or XST used alone. Administration of 1X1S not only significantly decreased neurological deficit scores and infarct volumes and increased regional cerebral blood flow, but also inhibited the activation of both microglia and astrocytes in the hippocampus. Furthermore, administration of 1X1S significantly decreased the levels of MDA and ROS with concomitant increases in the levels of antioxidant activity (SOD, CAT and GSH) in the brain tissues as compared with SLI and XST used alone. Moreover, administration of 1X1S remarkably upregulated the expression of Nrf-2, HO-1 and NQO-1, and downregulated the expression of Keap1 and facilitated the nuclear translocation of Nrf-2 in the brain tissues as compared with XST used alone. Our study demonstrates that a combination of 1X1S effectively protects MCAO/R injury via suppressing oxidative stress and the Nrf-2/Keap1 pathway.
Introduction
Stroke still remains a major cause of death and disability worldwide with serious long-term physical and cognitive disabilities that contribute to the rising costs of health care, despite all efforts of neuroscience community [1, 2] . Nearly 60%-70% of stroke is triggered by ischemia [3] , which is characterized by the occlusion of blood vessels through the formation of an obstructive thrombus or embolus. Currently, advanced intravascular procedures and thrombolytic treatment with tissue plasminogen activator agent are the only existing pharmacological therapies for the acute phase of stroke, which can effectively reduce functional deficits if given within an optimal time window in stroke patients [4] . However, the challenge of reperfusion injury remains for this thrombolytic treatment. Reperfusion after ischemia leads to neuronal injury and death, including the release of nitric oxide, excitatory amino acids, cytokines, and free radicals, mitochondrial respiratory enzymes damage, microglia activation, cerebral microcirculatory disturbance and even death of neurons [5, 6] . Therefore, protecting the brain from reperfusion injury after ischemia is an alternative for therapy of stroke. Both the occlusion of blood supply to the brain and cerebral ischemia result in the rapid onset of neurological injury. The treatment of ischemic stroke has important strategic approaches, including the repair of infarct damage and the improvement of functional recovery. Numerous studies have confirmed that the decrease of the regional cerebral blood flow (rCBF) and a series of oxidative stress and inflammatory reactions are major contributors to the pathogenesis of ischemic stroke. Oxidative stress, during which excessive reactive oxygen species (ROS) are produced, is a core pathological component of brain ischemia-reperfusion injury causing neuronal malfunction and cell death [7, 8] . Nuclear factor erythroid 2-related factor 2 (Nrf-2), a newly discovered gene transcription factor with high sensitivity to oxidative stress, is a major component in the kelch-like ECH-associated protein 1 (Keap1)-Nrf-2/antioxidant response element (ARE) antioxidant system. In physiological conditions, Nrf-2 is kept inactivated in association with Keap1 in the cytoplasm. When oxidative stress occurs, ROS may bring conformational changes to cause Nrf-2 activation. Nrf-2 dissociates from Keap1 and combines with ARE in the nucleus to initiate gene expression of heme-oxygenase-1 (HO-1) and other antioxidant enzymes, such as NAD(P)H quinone oxidoreductase (NQO-1), superoxide dismutase (SOD), catalase (CAT), malondialdehyde (MDA) and glutathione (GSH) [9, 10] . The Nrf-2/Keap1 pathway has been shown to play an important neuroprotective role in brain injury after ischemic stroke [11, 12] . In contrast with Western countries, China has many herbs and herbal standardized preparations for the clinical treatment of ischemic stroke. Danshen, the dried root or rhizome of Salviae miltiorrhizae Bge (SM), and Sanqi, the root of Panax notoginseng (Burk), have been widely used in China or other oriental countries for the treatment of cerebrovascular and cardiovascular conditions, such as to cure heart disease, ischemic stroke, and acute intracerebral hemorrhage [13, 14] . Salvianolate lyophilized injection (SLI), which is composed of the Danshen aqueous extraction, has been approved in the treatment of stroke by the State Food and Drug Administration in China since 2011. Furthermore, the salutary effect of the SLI components on cerebrovascular disease is widely reported [15, 16] . Xueshuantong for injection (lyophilized) (XST) is a standardized product extracted from Sanqi. SLI is used extensively for the treatment of cardiovascular disease, cerebrovascular disease, and diabetes in China [17] . Many studies suggest that SLI has increased myocardial microvascular reflow, promoted cardiac functional recovery and alleviated hepatocyte injury through attenuation of oxidative stress, and XST had decreased proteinuria through its suppression of oxidative stress [18] [19] [20] . Although those studies reported that the SLI and XST used alone have an oxidative stress effect, there is no report on the effect of SLI and XST protecting against ischemic injury in MCAO/R rats through its suppression of oxidative stress. Therefore, we wanted to study the effects of SLI and XST in protecting against antioxidative stress in MCAO/R rats. Additionally, we investigated whether the combined use strategy can compensate for their own disadvantages in the treatment of stroke or have stronger effects than the drug used alone.
Materials and methods
Drugs and reagents SLI, provided by Tianjin Tasly Pharmaceutical Co, Ltd (Tianjin, China), was authenticated and standardized in accordance with the Pharmacopoeia of China 2011. SLI were multiple salvianolic acids, primarily including salvianolic acid B (Sal B) (62.1%), salvianolic acid E (Sal E) (1.8%), lithospermic acid (LA) (3.7%) and rosmarinic acid (RA) (4.5%) [21] [22] [23] . XST was obtained from Wuzhou Pharmaceutical Co, Ltd (Wuzhou, China). The manufacturing technology was taken from the "Pharmacopoeia of China 2010." The HPLC fingerprint shows that it contains ginsenosides Rg1 (48.1%), ginsenosides Rb1 (27.8%), notoginsenoside R1 (11.1%), ginsenosides Re (5.5%), ginsenosides Rd (1.3%), notoginsenoside Ra (1.1%), and 20-Oglucoginsenoside Rf (0.7%) [24, 25] . The structures of these constituents are shown in Figure 1 . In this study, SLI and XST were freshly prepared in 0.9% normal saline before use. Edaravone injection (batch number: H20031342) was purchased from Nanjing Simcere Pharma Co, Ltd (Nanjing, China).
Chloral hydrate (batch number: Q/12HB 4218-2009) was purchased from Tianjin Kermel Chemical Reagent Co, Ltd (Tianjin, China), freshly prepared to a 3.5% solution with saline before experiments. Nissl stain kit, H&E kit, DAB substrate kit and crystal violet stain kit were purchased from Boster (Wuhan, China). BCA protein assay kit was purchased from CWBIO (China). Rabbit anti-rat monoclonal antibodies for glial fibrillary acidic protein (GFAP, ab7260), ionized calcium binding adaptor molecule-1 (IBA-1, ab178680), Nrf-2 (ab31163), NQO-1 (ab34173), HO-1 (ab68477), Keap1 (ab66620) and β-actin (ab8227) were purchased from Abcam (Massachusetts, USA). Secondary antibodies were purchased from Zhongshan Golden Bridge Biotechnology Co, Ltd (Beijing, China). Hoechst 33258 was bought from Beyotime (Haimen, China). TRIzol reagent was purchased from Life Technologies (USA).
Animals
Adult male Wistar rats (10 to 13 weeks old, 250-300 g) were purchased from Vital River Laboratory Animal Technology Co, Ltd (Beijing, China). The animals were housed in an airconditioned room (temperature, 22-25 °C; relative humidity, 55%±5%), and kept on a light/dark cycle of 12/12 h. Free access to food and drinking water was allowed throughout the study. Each rat was used only once. All animal manipulations were performed in accordance with European Community Guidelines for Animal Care and approved by the Committee at Tianjin University of Traditional Chinese Medicine in China (TCM-LAEC2015028). All experiments involving animals are reported in accordance with the animal research: reporting in vivo experiments (ARRIVE) guidelines.
Focal cerebral ischemia-reperfusion injury model
Focal cerebral ischemia-reperfusion was induced with minor modification of intraluminal MCAO as previously described [26] [27] [28] . The left common carotid artery (CCA) was exposed at its bifurcation using a midline cervical incision. The external carotid artery (ECA), internal carotid artery (ICA), and common carotid artery (CCA) were ligated using a 4-0 silk suture. The ECA was later transected, and a 3-0 nylon monofilament suture was inserted from the ECA into the ICA until reaching the origin of the MCA. The suture was advanced into the ICA until the MCA flow was <30% of baseline in order to exclude incomplete ischemia. The focal cerebral ischemia was confirmed by obvious changes of rCBF on a laser Doppler flow meter (2 mm posterior and 6 mm lateral to bregma on the right parietal skull). After 1.5 h of MCA occlusion, reperfusion was simulated by gently removing the filament. Finally, the distal two collar sutures were further tightened and trimmed. The animals were allowed food and water ad libitum. Core temperature was recorded continuously using a rectal probe, and a heating pad was used to maintain rectal temperature at 36.5-37.5 °C.
Drug administration
The rats were randomly divided into the following 7 groups: control group (NOR), MCAO/R group (MOD), SLI group (21 mg/kg, SLI), XST group (100 mg/kg, XST), SLI combined with XST group (XST 100 mg/kg: SLI 21 mg/kg, 1X1S), SLI combined with XST group (XST 50 mg/kg: SLI 10.5 mg/kg, 1/2X1/2S), and edaravone group (as a positive control drug, 6 mL/kg, EDI). SLI and XST were freshly dissolved in normal saline before use. SLI and XST initially used intravenous injection (iv) 3 h after MCAO/R and daily for 3 d. The shamoperated group and model-vehicle group were treated with isodose saline. In all experiments, the data were collected by a blinded, randomized and controlled design. Number of animals in each group for determination of each parameter can be observed in Table 1 .
Measurement of weight, neurological deficit score and mortality Body weight was monitored before surgery (0 d) and at d 3 (3 d) after surgery using a CS2000 Compact Digital Scale (Ohaus, Parsippany, NJ, USA). A modified neurological severity score (mNSS) evaluation was performed before MCAO/R and at 3 d after MCAO by an investigator who was blinded to the experimental groups [29] . mNSS is a composite of motor, sensory, balance and reflex tests. The detailed methods and scorings for these components are listed in Table 2 . Neurological function was graded on a scale of 0 to 18 (normal score 0; maximal deficit score 18) with one point awarded for the exhibition of specific abnormal behavior or for lack of a tested reflex. A greater impairment of normal function results in a higher score. The number of dead animals in each group was counted, and the mortality rate is presented as a percentage of rats that died 3 d after MCAO/R to the total animals in each group.
Regional cerebral blood flow (rCBF) measurements After 3 d, the rats were deeply anesthetized with an intraperitoneal injection of chloral hydrate, and core body temperature was maintained at 37 °C to 38 °C by a heating pad; animals underwent a right unilateral craniotomy. Regional CBF within the right hemisphere was measured using laser Doppler flowmetry. The data were analyzed using a moorLDIMeasV60 data acquisition and analysis system. Measurement of SOD, CAT, MDA and GSH SOD, CAT, MDA and GSH in brain tissues were determined with kits following the manufacturer's instructions (Nanjing Jiancheng Bioengineering Institute, China).
Detection of ROS generation
ROS detection was performed as previously described [30] . Briefly, the brain homogenates were diluted with ice-cold phosphate-buffered saline (PBS) at a 1:20 ratio and after adding 2′,7′-dichlorofluorescein diacetate (DCFH-DA, 10 μmol/L), this mixture was incubated at 37 °C for 45 min for the conversion of DCFH-DA to 2′,7′-dichlorofluorescein (DCF). Excitation was measured at 485 nm, and emission was measured at 525 nm. ROS formation was quantified from a DCF standard curve, and data were expressed as pmole DCF formed/min/mg protein.
Nissl and H&E staining After 3 d, the rats were deeply anesthetized and killed by cardiac perfusion with 250 mL normal saline and 400 mL 4% paraformaldehyde successively. Next, the brains were 
Measurement of lesion volumes
The brains were fixed by cardiac perfusion with saline followed by perfusion and immersion in 4% paraformaldehyde before being embedded in paraffin. Five coronal sections of tissue were processed and stained with crystal violet for calculation of volumes of cerebral infarction and presented as a percentage of the lesion compared with the contralateral hemisphere. The sections were examined under a light microscope (Leica Microsystems). Lesion volume was analyzed with ImageJ software (Wayne Rasband, National Institutes of Health, USA). Lesion percent was calculated with the formula lesion percent (%)=(ipsilateral ischemic hemisphere volume− contralateral ischemic hemisphere volume)/contralateral ischemic hemisphere volume×100.
Immunohistochemistry analysis
Brain sections were immersed in 0.3% hydrogen peroxide to block intrinsic peroxidase and were treated with 5% bovine serum to block any nonspecific antibody responses; the sections were incubated with primary antibodies against IBA-1 (1:200) and GFAP (1:200), then incubated with secondary antibody (1:200) for 1 h at 37 °C. Immunostaining was visualized by using a DAB substrate kit. The numbers of IBA-1 and GFAP per section were counted by an investigator who was blinded to the experimental groups. Images were captured through at least five randomly selected fields from three separate sections of each sample using a light microscope (Leica DM750M, Wetzlar, Germany) at magnification of 200×. The mean value of five fields for IBA-1 and GFAP were calculated for the statistical analysis.
Protein extraction and Western blotting Rats survived for 3 d after stroke onset was killed by overdose of isoflurane. Samples were obtained from the ischemic penumbra. Protein was extracted from brain tissues, and the protein concentration of each sample was determined using the BCA Protein Assay Kit. Next, 10 μg of the samples were loaded per lane. The primary antibody against GFAP (1:1000), IBA-1 (1:1000), Nrf-2 (1:1000), HO-1 (1:1000), NQO-1 (1:1000), Keap1 (1:1000) and β-actin (1:1000) were used. β-Actin was used as a control. After washing with TBS-T, the membrane was incubated with horseradish peroxidase-conjugated secondary antibody (1:10 000) at room temperature for 60 min. The relative intensities of the bands were measured by ImageJ software.
RNA isolation and quantitative real-time qPCR Seventy-two hours after MCAO, rats were deeply anesthetized and perfused through the heart with cold PBS. Total RNA was isolated using TRIzol reagent and processed for cDNA followed by quantitative real-time polymerase chain reaction (PCR) as previously described [31] . The specific primer pairs (Sangon Technology Co, Ltd, Shanghai, China) are listed in Table 3 . The mRNA levels of each cytokine were normalized to the level of β-actin, and the results were expressed as fold change of the threshold cycle (Ct) value relative to shamoperated controls using the 2 −ΔΔCt method. All samples were analyzed in triplicate.
Immunofluorescence analysis
Immunofluorescence staining for Nrf-2 and Keap1 was performed. Polyclonal antibodies against Nrf-2 and Keap1 were diluted to 1:200 and 1:100, respectively, in phosphate-buffered saline. Each section was washed and incubated with secondary antibody Alexa Flur488 mouse anti-rabbit IgG (1:200) and rhodamine (TRITC) goat anti-rabbit IgG (1:200), respectively, at 37 °C for 1 h. Hoechst 33258 (50 μL) was applied to stain the nucleus. Images were captured using a confocal microscope (Nikon, Japan). Five non-overlapping fields of one slice were randomly observed under a magnification of 10×10 or 10×20 in images. To quantitatively analyze protein expression, ImagePro Plus software was applied.
Statistical analysis
The results are expressed as the mean±standard deviation (SD). Differences between groups were evaluated by one-way Table 3 . The specific primer pairs used in polymerase chain reaction.
Gene
Primer pair (5'-3') F, forward; R, reverse
analysis of variance (ANOVA) with LSD post hoc analysis. SPSS software version 17.0 was used for statistical analysis; P-values <0.05 were considered to be statistically significant and extremely significant when P<0.01.
Results
1X1S increases body weight and improves behavioral outcomes in I/R-treated rats After 3 d of treatment with SLI, XST, EDI, 1X1S and saline, we evaluated the effects of SLI, XST, EDI and 1X1S in MCAO/R rats on body weight, neurological deficits and survival (Figure 2) . As shown in Figure 2B -2D, the MOD group exhibited significantly decreased body weight, which was significantly attenuated in the 1X1S, XST, SLI and EDI groups. As shown in Figure 2D , there was a marked decline in I/R neurological score, while the 1X1S, XST, SLI and EDI treatments resulted in a statistically significant improvement in neurobehavioral deficits compared with the MOD group. However, there were no significant changes in the percent survival of the treatment groups compared with the MOD group ( Figure 2E ). When compared with the EDI group, the SLI, XST and 1X1S groups exhibited no significantly changed body weight and neurological scores. The 1/2X1/2S treatment group exhibited no significantly increased body weight and decreased neurobehavioral deficits compared with the MOD group.
1X1S increases regional cerebral blood flow (rCBF) in I/R-treated rats
The rCBF was determined by a laser Doppler flowmetry system in the different groups, as shown in Figure 3A -3G, and the quantification of the results is shown in Figure 3H . The administration of EDI, SLI, XST and 1X1S resulted in a significant increase in rCBF at 72 h after reperfusion versus the MOD group. There was a significant decrease in the MOD group versus the NOR group. When compared to the EDI group, the SLI, XST and 1X1S groups exhibited no significant increases in rCBF. The 1/2X1/2S treatment group showed no significant increases in rCBF compared with the MOD group.
1X1S reduces lesion volumes and ameliorates histopathological damage in I/R-treated rats
Lesion volumes were evaluated in mouse brains by crystal violet staining after I/R injury. Representative samples of crystal violet-stained brain sections are shown in Figure 4A , with cor- responding lesion volumes and statistical data being shown in Figure 4B . Lesion volumes were significantly increased in the I/R operative group, whereas SLI, XST, EDI and 1X1S reduced the lesion volumes induced by I/R. Figure 4C shows the histopathological changes after 1.5 h of occlusion and 72 h of reperfusion by H&E staining, and the result showed that SLI, XST, EDI and 1X1S treatment ameliorated histopathological damage in I/R-treated rats. Compared with the EDI group, the SLI, XST and 1X1S groups exhibited no significant reductions in lesion volumes. The 1X1S treatment group showed significant decreases in lesion volumes compared with the SLI group and the XST group. Moreover, the lesion volumes in the 1/2X1/2S group showed no decrease compared with the MOD group.
1X1S attenuated neuronal injury after I/R-treated rats
Nissl staining was used to reveal neuronal injury in the penumbra of ischemic cortex at 3 d after treatment. In the NOR group, normal neurons had normal morphology with a clear nucleolus, abundant cytoplasm, and intact structure, which were arranged orderly. In the MOD group, most of neurons in the ischemic penumbra had enlarged intercellular spaces were disappearance of the Nissl body, were shrunken and deep stained, and/or had nuclear pyknosis, which are the indications of the injury induced by I/R. However, these characteristic morphological changes were not observed in the NOR group. Compared to the SLI group and the XST group, these characteristic morphological changes were rarely observed in the 1X1S group due to the neuroprotective effect of SLI combined with XST ( Figure 5 ). Compared with the EDI group, the SLI, XST and 1X1S groups exhibited no significant increases in the number of intact cells. Moreover, the number of intact cells in the 1/2X1/2S group had not been increased compared with the MOD group.
1X1S elevates the levels of SOD, CAT and GSH and reduces the level of MDA in I/R-treated rats Antioxidant enzyme (SOD, CAT and GSH) levels and MDA content were examined in order to assess the protective effect of 1X1S treatment on I/R rats. As shown in Figure 6 , after I/R injury, higher level of MDA and lower levels of SOD, CAT and GSH were present in the MOD group compared with NOR group. SLI, XST, EDI and 1X1S treatment significantly elevated the levels of SOD, CAT and GSH and reduced the level of MDA in brain tissue compared with the MOD group. Treatment of 1X1S could upregulate the levels of SOD, CAT and GSH and downregulate the level of MDA compared with the SLI group and the XST group. When compared with the EDI group, higher level of MDA and lower levels of SOD, CAT and GSH were present in the SLI group and the XST group.
1X1S reduces the level of reactive oxygen species (ROS) in I/R-treated rats
Previous studies have demonstrated that ROS plays a key role in the pathophysiological response of the brain after I/R injury [32] . The results showed that I/R injury significantly increased ROS production compared to the normal rats. Conversely, the I/R rats that received SLI, XST, EDI and 1X1S treatment had significantly less ROS generation level in comparison to the I/R rats. Compared with the EDI group, higher levels of ROS were present in the SLI group and the XST group. Treatment of 1X1S could decrease the level ROS compared with the SLI group and the XST group ( Figure 7 ).
1X1S suppressed activation of microglia and astrocytes in the I/R-treated rats
Neuronal death in cerebral I/R injury is associated with astrocytosis and microgliosis. The counted number of microglia and astrocyte cells that positively reacted to IBA-1 and GFAP were markedly increased in the ipsilateral hippocampus of MCAO/R rats ( Figure 8A, 8B ). Compared to that in MOD rats, decreases of IBA-1 ( Figure 8B ) and GFAP ( Figure 8II ) immunoreactivity were found in the ipsilateral hippocampus of SLI-, XST-and 1X1S-treated MCAO/R rats. Figure 8C -8E shows that stroke upregulated brain level of GFAP and IBA-1 protein and mRNA, and SLI, XST and 1X1S treatment reduced their expression in MOD rats. The MOD rats had significantly higher levels of GFAP and IBA-1 protein and mRNA than NOR animals and SLI-, XST-and 1X1S-treated animals. We found that the 1X1S group had no significant difference compared with SLI and XST in levels of GFAP and IBA-1 proteins but had a significant difference in levels of GFAP and IBA-1 mRNA. These results suggest that SLI, XST and 1X1S could inhibit the activation of both microglia and astrocytes induced by cerebral ischemia/reperfusion.
1X1S treatment significantly increased the levels of HO-1, NQO-1 and Nrf-2 and reduced Keap1 expression in I/R-treated rats To understand the mechanism of 1X1S on cerebral protection, the expression of Nrf-2, HO-1, NQO-1 and Keap1 in I/R rat brain tissues was measured using Western blotting and realtime qPCR (Figure 9A-9C) . The Western blotting and realtime qPCR results showed that the SLI, XST, EDI and 1X1S treatments significantly increased the expression of HO-1, NQO-1 and Nrf-2 and reduced the expression of the Keap1 in the ischemic brains compared with the MOD group. 1X1S remarkably upregulated the expression of Nrf-2, HO-1 and NQO-1 compared with the XST and downregulated the expression of Keap1 compared with the SLI and XST.
1X1S altered Nrf-2 and Keap1 expression in I/R-treated rats
To clarify whether the Nrf-2/Keap1 pathway was involved in the antioxidative stress response of 1X1S, we examined the cytoplasmic expression and nuclear translocation of Keap1 and Nrf-2 in I/R-treated rat brain tissues ( Figure 10 ). According to the immunofluorescence analysis, in the NOR group, Nrf-2 was localized to the cytoplasm. In SLI-, XST-, EDI-and 1X1S-treated groups, downregulated Nrf-2 expression with cytoplasmic localization and a subsequent profound upregulated Nrf-2 expression was observed in the nucleus. In SLI-, XST-, EDI-and 1X1S-treated rats, a nuclear translocation of Nrf-2 and a decrease in Keap1 expression were observed. However, 1X1S remarkably downregulated the expression of Keap1 and facilitated the nuclear translocation of Nrf-2 compared with XST. These results indicate that SLI is major factor in the antioxidative effects of 1X1S.
Discussion
In the present study, we used an MCAO/R rat model to determine the effects of 1X1S following acute ischemic stroke through the activation of the Nrf-2/Keap1 antioxidant pathway. Our results show that body weight, neurobehavioral deficits, lesion size, glial activation, rCBF and neuronal injury were decreased in this model by SLI, XST, EDI and 1X1S treatment. Additionally, the treated rats exhibited decreased ROS and MDA activities and increased levels of SOD, CAT and GSH compared to the MOD group. Furthermore, SLI combined with XST protected the brain more effectively than the SLI and XST used alone. Furthermore, 1X1S and edaravone post-treatment remarkably reduced infarct volume and improved neurological function. These results indicated that 1X1S could be a potential clinical cerebral I/R injury therapy. SLI, a water-soluble component of Salviae miltiorrhizae roots (Danshen in Chinese) and has been widely used in China for the treatment of cerebrovascular conditions, such as ischemic stroke [33] . XST, a freeze-dried saponin powder injection of Panax notoginseng Saponin, is used to treatment stroke, chest stuffiness and pains, and central retinal vein occlusion [34] . Many studies suggest that SLI and XST have strong scavenging activity against oxidative stress [18, 20, 33] . Although those reported that the SLI and XST used alone have oxidative stress effect, there is no report on the effect of SLI and XST protecting against ischemic injury in MCAO/R rats through its suppression of oxidative stress. However, oxidative stress has been found to play a crucial role in ischemic stroke [35, 36] . EDI, a potent scavenger of hydroxyl radicals, is widely used to treat acute ischemic stroke [37] . Therefore, in the current study, the antioxidative effects of SLI, XST and EDI in cerebral I/R injuries were compared, and possible mechanisms of the brainprotective effect of SLI and XST were suggested. Additionally, we wanted to investigate whether the combined use strategy can compensate for their own disadvantages for the treatment of stroke or have stronger effects than the drugs used alone and designed 1X1S and 1/2X1/2S groups. Our results show that SLI and XST did not have significant differences compared with EDI, while 1X1S protected the brain more effectively than the SLI and XST used alone in MCAO/R rats. However, 1/2X1/2S did not improve body weight, neurobehavioral deficits, lesion size, glial activation, rCBF and neuronal injury in the MCAO/R rats compared with the MOD group.
Reactive gliosis associated with ischemic stroke involves both astrocytes and microglia, which is an important component of the cellular and molecular pathways involved in stroke-induced destructive responses [38] . In our study, MCAO/R injury increased the expression of GFAP and IBA-1 expression, while the expression of these markers was reduced in rats treated with SLI, XST, EDI and 1X1S. These observations suggest that the neuroprotective properties of SLI, XST, EDI and IXIS were caused by inhibiting the proliferation of glial cells.
The process of ischemia-reperfusion is multifactorial, and there are several mechanisms involved in the pathogenesis. There is ample evidence that I/R injury is in part caused by an excessive generation of ROS [7] . I/R produces excess ROS while downregulating the expression of SOD, CAT and GSH, resulting in oxidative stress in the brain. Oxidative stress plays a central role among the various factors contributing to I/R brain damage [39] . Nrf-2 is a key regulator of endogenous antioxidant defense [40] . HO-1 is a rate-limiting enzyme [41] . At the transcriptional level, HO-1 and other antioxidant enzymes, such as NQO-1, SOD, CAT, GSH and MDA, are mediated by the transcription factor Nrf-2 [42, 43] . Under physiological situations, Nrf-2 is bound by Keap1 and resides in the cytoplasm before it is targeted for proteasomal degradation [44] [45] [46] . Recently, several scientific studies have provided experimental evidence that the Nrf-2/Keap1 pathway is a potential therapeutic target in brain injury after ischemic stroke [11, 12] . Previously, cerebral ischemia/reperfusion injury was confirmed to be related to these genes [47, 48] . To explore the possible mechanism of 1X1S antioxidant protection, we investigated the effects of 1X1S on the expression of interference of the Nrf-2/ Keap1 pathway genes. Our results showed that 1X1S upregulated expression of HO-1 and NQO-1, significantly elevated the levels of SOD, CAT and GSH, and reduced the levels of MDA and Keap1 in brain tissue when compared with the MOD group. These results suggested that 1X1S could attenuate I/R injury-induced oxidative stress via the Nrf-2/Keap1 pathway.
As previously described [17, 28] , SLI and XST consist of many bioactive compounds, such as salvianolic acids (B, E), rosmarinic acid and lithospermic acid, and ginsenosides (Rg1, Rb1, R1, Re and Rd), some of which display neuroprotective effects after cerebral I/R injury. Salvianolic acid B exerts various pharmacological activities, such as anti-inflammation, antioxidation, promotion of cellular proliferation, anti-tumor and preservation of normal cell functions [49] . Rosmarinic acid has significant neuroprotective effects during cerebral I/R injury, such as attenuated BBB breakdown, decreased infarct volume and reduced HMGB1 expression in ischemic brain tissue. Ginsenoside Rb1 weakens the activity of microglia and decreases the upregulation of brain tissue mRNA of TNF-α and interleukin-1 (IL-1), IL-β, and IL-6 in the brain induced by systemic lipopolysaccharide (LPS) treatment in C57BL/6 mice [50, 51] . Ginsenoside Rg1 attenuates BBB disruption by downregulating the expression of aquaporin 4 induced via ischemic stroke in animals [52] . Ginsenoside Rd improves stroke outcome and attenuate mitochondrial dysfunction after transient focal ischemia by reducing inflammatory response and protecting mitochondria [53, 54] . Notoginsenoside R1 protects the viability of rat neuronal cells in primary cultured mouse cortical neurons induced by glutamate interference [55] . Based on these bioactive compounds, it is likely that 1X1S could protect against isch- emic stroke through various ways, although our study only explored a part of all pathways. This current study was conducted to elucidate the mechanism of 1X1S against focal cerebral I/R injury in rats through attenuation of oxidative stress ( Figure 11 ). I/R injury led to additional ROS production. Excessive ROS caused oxidative stress. Subsequently, under oxidative stress, the Keap1-Nrf-2 Figure 11 . Graphical abstract shows the protective mechanism of 1X1S against cerebral injury following focal cerebral ischemia and reperfusion via Nrf-2/Keap1 pathway. effectively protected MCAO/R injury against oxidative stress, which was largely dependent on the upregulation of the Nrf-2/Keap1 pathway. It might be the first report that shows that 1X1S can potentially ameliorate I/R injury-induced oxidative stress in the MCAO/R rat's brain. Although we demonstrated the cerebral protective effect of 1X1S in MCAO/R rats, we have yet to reveal the underlying mechanisms of 1X1S on Nrf-2/Keap1 signaling pathways, which is a limitation of the study. However, it is worthwhile to decipher in future studies.
In conclusion, as illustrated in Figure 11 , 1X1S exhibits protective effects against cerebral I/R injury in an MCAO model, which was demonstrated by improved neurological scores, reduced lesion volume and increased regional cerebral blood flow. The mechanism is possibly attributed to activation of the Nrf-2/Keap1 pathway.
